Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8501-8511

  Fislier, Larry W ^a   Jain, Alka ^b   Tayback, Matt ^b   Fedarko, Neal S ^b,c  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JHAAC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE SIALOPROTEIN; DENTIN MATRIX PROTEIN 1; DENTIN SIALOPHOSPHOPROTEIN; GELATINASE A; GELATINASE B; GLYCOPROTEIN; INTEGRIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; MATRIX METALLOPROTEINASE; OSTEOPONTIN; SIALOPROTEIN; SMALL INTEGRIN BINDING LIGAND N LINKED GLYCOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER; CANCER GROWTH; COLON CANCER; CONTROLLED STUDY; DNA FINGERPRINTING; DNA MICROARRAY; EARLY CANCER; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY CANCER; LUNG CANCER; MULTIGENE FAMILY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECTUM CANCER; STOMACH CANCER; THYROID CANCER; UTERUS CANCER;

DNA PROBES; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; LIGANDS; MATRIX METALLOPROTEINASES; NEOPLASMS; OSTEOPONTIN; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN PRECURSORS; RNA, MESSENGER; RNA, NEOPLASM; SIALOGLYCOPROTEINS;

EID: 11144227593     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1072     Document Type: Article

References (86)

1. Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 2003;44(Suppl 1);33-40.
2. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994;145:610-23.
3. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10;184-90.
4. Bellahcene A, Merville MP, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 1994;54:2823-6.
5. Waltregny D, Bellahcene A, de Leval X, et al. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 2000;15:834-43.
6. Waltregny D, Bellahcene A, Van Riet I, et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst (Bethesda) 1998;90:1000-8.
7. Bellahcene A, Maloujahmoum N, Fisher LW, et al. Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 1997;61:183-8.
8. Bellahcene A, Albert V, Pollina L, et al. Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid 1998;8:637-41.
9. Chaplet M, De Leval L, Waltregny D, et al. Dentin matrix protein 1 is expressed in human lung cancer. J Bone Miner Res 2003;18:1506-12.
10. Rowe PS, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000;67:54-68.
11. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGS) bind and activate specific matrix metalloproteinases. FASEB J 2004:18:734-6.
12. Zhumabayeva B, Diatchenko L, Chenchik A, Sieben PD. Use of SMART-generated cDNA for gene expression studies in multiple human tumors. Biotechniques 2001;30:158-63.
13. Fisher LW, McBride OW, Termine JD, Young MF. Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J Biol Chem 1990;265:2347-51.
14. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986;83:8819-23.
15. Hirst KL, Simmons D, Feng J, et al. Elucidation of the sequence and the genomic organization of the human dentin matrix acidic phosphoprotein 1 (DMPI) gene: exclusion of the locus from a causative role in the pathogenesis of dentinogenesis imperfecta type II. Genomics 1997;42:38-45.
16. Freije JM, Balbin M, Pendas AM, et al. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107.
17. Chenchik A, Zhu YY, Diatchenko L, Li R, Hill J, Siebert PD. Generation and use of high-quality cDNA from small amounts of total RNA by SMART PCR. In: Siebert P, Larrick J, editors. Gene Cloning and Analysis by RT-PCR. Natick, MA: Eaton Publishing; 1998. p, 305-19.
18. Blanquicett C, Johnson MR, Heslin M, Diasio RB. Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem 2002;303:209-14.
19. Rondinelli RH, Epner DE, Tricoli JV. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in late pathological stage human prostate cancer. Prostate Cancer Prostatic Dis 1997;1:66-72.
20. Aerts JL, Gonzales MI, Topalian SL. Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. Biotechniques 2004;36:84-6, 88, 90-1.
21. Zhumabayeva B, Chenchik A, Siebert PD, Herrler M. Disease profiling arrays: reverse format cDNA arrays complimentary to microarrays. Adv Biochem Eng Biotechnol 2004;86:191-213.
22. Thiebault K, Mazelin L, Pays L, et al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc Natl Acad Sci USA 2003;100:4173-8.
23. Liu S, Huang H, Lu X, et al. Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis. Mol Cancer Res 2003;1:665-73.
24. Iavarone C, Wolfgang C, Kumar V, et al. PAGE4 is a cytoplasmic protein that is expressed in normal prostate and in prostate cancers. Mol Cancer Ther 2002;1:329-35.
25. Egland KA, Kumar V, Duray P, Pastan I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther 2002;1:441-50.
26. Sers C, Husmann K, Nazarenko I, et al. The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells. Oncogene 2002;21:2829 -39.
27. Wiechen K, Diatchenko L, Agoulnik A, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001;159:1635-43.
28. Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 1996;69:350-3.
29. Detry C, Waltregny D, Quatresooz P, et al. Detection of bone sialoprotein in human (pre)neoplastic lesions of the uterine cervix. Calcif Tissue Int 2003;73:9-14.
30. Gillespie MT, Thomas RJ, Pu ZY, et al. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997;73:812-5.
31. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998;79:502-8.
32. Yeatman TJ, Chambers AF. Osteopontin and colon cancer progression. Clin Exp Metastasis 2003;20:85-90.
33. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (Bethesda) 2002;94:513-21.
34. Maeng HY, Choi DK, Takeuchi M, et al. Appearance of osteonectin- expressing fibroblastic cells in early rat stomach carcinogenesis and stomach tumors induced with N-methyl-N′-nitro-N-nitrosoguanidine. Jpn J Cancer Res 2002;93:960-7.
35. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-32.
36. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.
37. Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum Pathol 1998;29:1250-4.
38. Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001;171:215-22.
39. Chambers AF, Wilson SM, Kerkvliet N, et al. Osteopontin expression in lung cancer. Lung Cancer 1996;15:311-23.
40. Tunio GM, Hirota S, Nomura S, Kitamura Y. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. Arch Pathol Lab Med 1998;122:1087-90.
41. Lebeau A, Nerlich AG, Sauer U, Lichtinghagen R, Lohrs U. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res 1999;19:4257-64.
42. Onisto M, Riccio MP, Scannapieco P, et al. Gelatinase A/TlMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Int J Cancer 1995;63:621-6.
43. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996;56:190-6.
44. Ornstein DL, MacNab J, Cohn KH. Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer. Clin Exp Metastasis 1999;17:205-12.
45. Karakiulakis G, Papanikolaou C, Jankovic SM, et al. -Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 1997;17:158-68.
46. Collins HM, Morris TM, Watson SA. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 2001;84:1664-70.
47. Papadopoulou S, Scorilas A, Arnogianaki N, et al. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumour Biol 2001;22:383-9.
48. Mori M, Mimori K, Shiraishi T, et al. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 1997;74:316-21.
49. Ohtani H, Nagai T, Nagura H. Similarities of in situ mRNA expression between gelatinase A (MMP-2) and type I procollagen in human gastrointestinal carcinoma: comparison with granulation tissue reaction. Jpn J Cancer Res 1995;86:833-9.
50. Nakagawa H, Yagihashi S. Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung. Jpn J Cancer Res 1994;85:934-8.
51. Yamamoto M, Mohanam S, Sawaya R, et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996;56:384-92.
52. Suzuki M. Iizasa T, Fujisawa T, et al. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer. Invasion Metastasis 1998;18:134-41.
53. Creighton C, Hanash S. Expression of matrix metalloproteinase 9 (MMP-9/gelatinase B) in adenocarcinomas strongly correlated with expression of immune response genes. In Silico Biol 2003;3:301-11.
54. Chan CC, Menges M, Orzechowski HD, et al. Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Int J Colorectal Dis 2001;16:133-40.
55. Kitagawa Y, Kunimi K, Uchibayashi T, Sato H, Namiki M. Expression of messenger RNAs for membrane-type 1, 2, and 3 matrix metalloproteinases in human renal cell carcinomas. J Urol 1999;162:905-9.
56. Hagemann T, Gunawan B, Schulz M, Fuzesi L, Binder C. mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur J Cancer 2001;37:1839-46.
57. Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001;158:735-43.
58. Freije JM, Diez-Itza I, Balbin M, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994;269:16766-73.
59. Basset P. Bellocq JP, Anglard P, et al. Stromelysin-3 and other stromelysins in breast cancer: importance of epithelialstromal interactions during tumor progression. Cancer Treat Res 1996;83:353-67.
60. Iwata H, Kobayashi S, Iwase H, et al. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 1996;87:602-11.
61. Chenard MP, O'Siorain L, Shering S, et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996;69:448-51.
62. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 2000;87:1215-21.
63. Gallegos NC, Smales C, Savage FJ, Hembry RM, Boulos PB. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol 1995;4:21-9.
64. Matrisian LM, Wright J, Newell K, Witty JP. Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp 1994;24:152-61.
65. Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791-7.
66. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 1996;69:9-16.
67. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, et al. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996;148:519-26.
68. Imai K, Yokohama Y, Nakanishi I, et al. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995;270:6691-7.
69. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998;16:577-85.
70. Davidson B, Goldberg I, Liokumovich P, et al. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 1998;17:295-301.
71. Davidson B, Goldberg I, Kopolovic J, et al. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999;72:380-6.
72. Takeha S, Fujiyama Y, Bamba T, et al. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res 1997;88:72-81.
73. Parsons SL, Watson SA, Collins HM, et al. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 1998;78:1495-502.
74. Torii A, Kodera Y, Ito M, et al. Matrix metalloproteinase 9 in mucosally invasive gastric cancer. Gastric Cancer 1998;1:142-5.
75. Wang L, Zhang LH, Li YL, Liu Z. Expression of MMP-9 and MMP-9 mRNA in gastric carcinoma and its correlation with angiogenesis [in Chinese], Zhonghua Yi Xue Za Zhi 2003;83:782-6.
76. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-I, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000;17:673-81.
77. Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17:799-808.
78. Kremer EA, Chen Y, Suzuki K, Nagase H, Gorski JP. Hydroxyapatite induces autolytic degradation and inactivation of matrix metalloproteinase-1 and -3. J Bone Miner Res 1998;13:1890-902.
79. Roeb E, Dietrich CG, Winograd R, et al. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer (Phila) 2001;92:2680-91.
80. Inoue K, Kamada M, Slaton JW, et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002;8:1863-70.
81. Hirama M, Takahashi F, Takahashi K, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 2003;198:107-17.
82. Bellahcene A, Bonjean K, Fohr B, et al. Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res 2000;86:885-91.
83. Sainsbury JRC, Anderson TJ, Morgan DAL, Breast cancer. Br Med J 2000;321:745-50.
84. Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal and lobular breast carcinomas are characterized by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 2002;87:1105-11.
85. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, et al. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001;193:40-7.
86. Korkola JE, DeVries S, Fridlyand J, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003;63:7167-75.